ERBB2 and breast carcinoma: In the ATHENA registry, including 2251 patients with HER2-negative breast cancer, the superiority of paclitaxel over capecitabine to improve time-to-progression (TTP: 9.8 months vs. 7.0 months) and response rate (49% vs. 36%) was confirmed (not statistically tested) [15].